Brands, Medical Use, Clinical Data
Brands / Synonyms
Amen; Aragest; Aragest 5; Asconale; Clinofem; Clinovir; Colirest; Crinone; Curretab; Cycrin; Depo-Clinovir; Depo-Prodasone; Depo-Progestin; Depo-Promone; Depo-Provera; Depo-Subq Provera 104; Depomedroxyprogesterone acetate; Depot-Medroxyprogesterone acetate; DMPA; Farlutal; Farlutin; G-Farlutal; Gestapuran; Hematrol; Hydroxymethylprogesterone; Hysron; Indivina; Lunelle; Lutopolar; Lutoral; MAP; Med-Pro; Medroprogesterone Acetate; Medrossiprogesterone [Dcit]; Medroxiprogesterona [Inn-Spanish]; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteron acetate; Medroxyprogesterone; Medroxyprogesterone acetate; Medroxyprogesterone Base; Medroxyprogesteronum [Inn-Latin]; Meprate; Metigestrona; MPA; MPA Gyn 5; Nadigest; Nidaxin; Novo-Medrone; Oragest; Perlutex; Perlutex Leo; Prempro; Prempro/Premphase; Prodasone; Progestalfa; Progestasert; Progesterone; Progeston; Progevera; Prometrium; Provera; Proverone; Ralovera; Repromap; Repromix; Sirprogen; Sodelut G; Veramix
Used as a contraceptive and to treat amenorrhea, abnormal uterine bleeding, endometriosis, endometrial and renal cell carcinomas, and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), Pickwickian syndrome, and other hypercapnic pulmonary conditions.
Medroxyprogesterone is a synthetic progestin more potent than progesterone.
Mechanism of Action
Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
Rapidly absorbed from GI tract
Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.
Biotrnasformation / Drug Metabolism
1. Known or suspected pregnancy.
2. Undiagnosed vaginal bleeding.
3. Known or suspected malignancy of breast.
4. Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular
5. Significant liver disease.
6. Known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients.
No drug-drug interaction studies have been conducted with depo-subQ provera 104.
Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum
concentrations of MPA.
The pathologist should be advised of progestin therapy when relevant specimens are submitted. The physician should
be informed that certain endocrine and liver function tests, and blood components may be affected by progestin
(a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone,
(b) Plasma and urinary gonadotropin levels are decreased (e.g., LH, FSH).
(c) SHBG concentrations are decreased.
(d) T3-uptake values may decrease.
(e) There may be small changes in coagulation factors.
(f) Sulfobromophthalein and other liver function test values may be increased slightly.
(g) There may be small changes in lipid profiles.